A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (TRIDENT)

This is a Phase 2, single-arm study to evaluate the safety and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (PDAC).

Start Date27 Jan 2026

Sponsor / Collaborator

Corcept Therapeutics, Inc.

NCT06906341

/ RecruitingPhase 2

An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)

This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

Start Date11 Apr 2025

Sponsor / Collaborator

Corcept Therapeutics, Inc.

NCT05726292

/ RecruitingPhase 2IIT

A Randomized Phase II Trial of Neoadjuvant Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.

Start Date06 Jan 2025

Sponsor / Collaborator

The University of Chicago

100 Clinical Results associated with Relacorilant

100 Translational Medicine associated with Relacorilant

100 Patents (Medical) associated with Relacorilant

Literatures (Medical) associated with Relacorilant

01 Feb 2026·INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Gynecologic cancers in 2025: a year in review

Review

Author: Arenhardt, Martina Parenza ; Nogueira-Rodrigues, Angélica ; Tavares Filgueiras, Ana Beatriz ; Alves, Cassio Bona

Gynecologic cancers remain a leading cause of morbidity and mortality in women, and recent years have marked an inflection point through the consolidation of immunotherapy, the maturation of antibody-drug conjugates, and broader biomarker implementation. This narrative review synthesizes key clinical and translational advances across ovarian, endometrial, and cervical cancers in 2025, emphasizing implications for treatment selection and sequencing. In advanced ovarian cancer, TRUST re-examined surgical timing, supporting primary cytoreduction in selected resectable patients, whereas ICON8B suggested that weekly paclitaxel with carboplatin and bevacizumab may improve outcomes in high-risk disease. Platinum-resistant ovarian cancer saw the most disruptive progress: mirvetuximab soravtansine validated folate receptor-α as a therapeutic target, with overall survival benefit in high-expressing tumors; trastuzumab deruxtecan expanded actionable HER2 disease, with greatest activity in tumors rated 3+ by immunohistochemistry; and combination strategies, including relacorilant plus nab-paclitaxel and pembrolizumab plus weekly paclitaxel ± bevacizumab, delivered clinically meaningful survival signals, underscoring the need for harmonized biomarker strategies and proactive toxicity mitigation. In endometrial cancer, the Cancer Genome Atlas-based molecular classification increasingly informs risk stratification and adjuvant tailoring; long-term PORTEC-3 data refine escalation for p53-abnormal disease and de-escalation considerations for POLE-mutant tumors. In advanced disease, first-line chemo-immunotherapy has matured, with overall survival updates in mismatch repair-deficient tumors and a consistent progression-free survival benefit across diverse mismatch repair-proficient sub-groups, whereas adjuvant immunotherapy remains in evolution after KEYNOTE-B21. In cervical cancer, pembrolizumab added to definitive chemoradiotherapy set a new benchmark in locally advanced disease, and ultra-sensitive circulating tumor DNA analyses emerged as a powerful prognostic tool to enable post-treatment risk-adapted strategies. Collectively, the 2025 data set reinforces a "right therapy, right patient, right time" paradigm and prioritizes confirmatory antibody-drug conjugate trials, resistance biology, and dynamic biomarkers to translate gains into durable, equitable benefit.

01 Feb 2026·Lancet Diabetes & Endocrinology

Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study

Article

Author: Bourdeau, Isabelle ; Mathews, Joseph W ; Fazeli, Pouneh K ; Al-Karadsheh, Amer ; Elenkova, Atanaska ; Recasens, Monica ; Nya-Ngatchou, Jean J ; Yuen, Kevin C J ; Arnaldi, Giorgio ; Busch, Robert ; Sachmechi, Isaac ; Chmiel-Perzyńska, Iwona ; Feelders, Richard A ; Dresner-Pollak, Rivka ; Stigliano, Antonio ; Kirschner, Lawrence S ; Miller, Harold J ; Tudor, Iulia Cristina ; Abbott, Lisa ; Ownby, Jonathan ; Hannoush, Zeina C ; Auchus, Richard J ; Romanowski, Leszek ; Ranetti, Aurelian-Emil ; Hannoush, Zeina ; East, Honey E ; Silverstein, Julie ; Kargi, Atil Y ; Salvatori, Roberto ; Fassnacht, Martin ; Jabbour, Serge ; Araque, Katherine A ; Katselnik, Daniel ; Shimon, Ilan ; Wang, Christina ; Huang, Wenyu ; Geer, Eliza ; Rotman-Pikielny, Pnina ; Reincke, Martin ; Gordon, Murray B ; Aresta, Carmen ; Fazeli, Pouneh ; Badiu, Corin ; Moraitis, Andreas G ; Hamidi, Oksana ; Dobri, Georgiana ; Dobri, Georgiana A ; Donegan, Diane M ; Kesner-Hays, Amanda ; Garcia-Centeno, Rogelio ; Niculescu, Dan ; Preda, Cristina ; Terzolo, Massimo ; Dischinger, Ulrich ; Cannavò, Salvatore ; Pivonello, Rosario ; Drincic, Andjela ; Greenman, Yona ; Scaroni, Carla ; Miller, Harold ; Martino, Marianna ; Hand, Austin L ; Gilis-Januszewska, Aleksandra ; Isidori, Andrea ; Maduerio, Francisco JT ; Min, Le ; Heaney, Anthony ; Parker, John C ; Imran, Syed A ; Levine, Alice ; Lim, Jonea ; Rovner, Sergio ; Picó Alfonso, Antonio M ; Soto-Moreno, Alfonso ; Busch, Robert S ; Kautzky-Willer, Alexandra ; Donegan, Diane ; Rovner, Sergio S ; Yuen, Kevin CJ

BACKGROUND:

Relacorilant is a selective glucocorticoid receptor modulator designed to reduce excess cortisol activity by competing with cortisol for glucocorticoid receptor binding, mitigating the clinical manifestations of endogenous hypercortisolism (Cushing's syndrome). The aim of this study was to assess the efficacy and safety of relacorilant in adults with endogenous hypercortisolism.

METHODS:

This multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study enrolled adults with endogenous hypercortisolism and hypertension, hyperglycaemia, or both and was conducted at 77 study centres across 11 countries. Key inclusion criteria included being aged 18-80 years with at least two clinical signs or symptoms of hypercortisolism. In the open-label phase, patients received oral, once-daily relacorilant (escalation from 100 mg up to 400 mg) for 22 weeks. Patients who met response criteria were randomly assigned (1:1) by the interactive web response system to continue relacorilant 400 mg (or highest tolerated dose) or placebo for 12 weeks in the randomised-withdrawal phase. Participants and investigators were masked to treatment assignment. The primary outcome was the proportion of patients who lost hypertension response during the randomised-withdrawal phase compared between relacorilant and placebo at week 12. As per protocol, this outcome was assessed in all participants who received at least one dose of study drug in the study period (intention-to-treat population). Missing randomised-withdrawal week 12 values were considered a loss of response. Safety was assessed in all enrolled patients who received at least one dose of study drug in that period. This study is registered with ClinicalTrials.gov, NCT03697109.

FINDINGS:

Between Oct 16, 2018, and April 15, 2024, 404 patients were screened, 152 were enrolled, and 95 completed the open-label relacorilant phase. 62 patients met response criteria and were randomly assigned to relacorilant (30 total participants [21 met hypertension response criteria]) or placebo (32 total participants [22 met hypertension response criteria]). In the 30 participants in the relacorilant group, the mean age was 46·6 years (SD 11·0), 22 (73%) were female, and eight (27%) were male. In the 32 participants in the placebo group, the mean age was 48·8 years (SD 14·4), 26 (81%) were female, and six (19%) were male. During the randomised-withdrawal phase, significantly more patients with baseline hypertension who were randomly assigned to placebo lost hypertension control compared with those who continued relacorilant (proportion difference 34%; odds ratio 0·17 [95% CI 0·04-0·77]; p=0·022). In the randomised-withdrawal phase safety population, the most common adverse events in the 30 participants given relacorilant and the 32 participants given placebo were back pain (5 [17%] vs 6 [19%]), acne (3 [10%] vs 0), arthralgia (3 [10%] vs 3 [9%]), bursitis (3 [10%] vs 0), headache (3 [10%] vs 4 [13%]), and insomnia (0 vs 4 [13%]). There were no cases of excessive glucocorticoid receptor antagonism, adrenal insufficiency, vaginal bleeding associated with endometrial hypertrophy, drug-induced hypokalaemia, or drug-induced QT interval prolongation.

INTERPRETATION:

Patients treated with relacorilant were more likely to maintain hypertension control compared with patients treated with placebo. The findings support consideration of relacorilant as a therapeutic option to reduce the harmful and debilitating effects of endogenous hypercortisolism.

FUNDING:

Corcept Therapeutics.

01 Oct 2025·Med

Targeting the glucocorticoid receptor as a therapeutic strategy for ovarian cancer: The ROSELLA study

Article

Author: Matulonis, Ursula A ; Lantsman, Taliya

The ROSELLA trial tested the combination of intermittently dosed relacorilant, a novel glucocorticoid receptor antagonist, plus nab-paclitaxel versus nab-paclitaxel alone in recurrent platinum-resistant ovarian cancer (PROC).¹ Interim results showed, for the combination, a 1-month improvement in median progression-free survival (PFS) and overall survival improvement versus single-agent nab-paclitaxel. Toxicities were higher in the combination arm versus single-agent nab-paclitaxel.

News (Medical) associated with Relacorilant

30 Mar 2026

·www.biospace.com

Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session

Hypercortisolism identified in 27.3 percent of patients with resistant hypertension REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented late-breaking data from its MOMENTUM trial examining the prevalence of endogenous hypercortisolism in patients with resistant hypertension at the 2026 American College of Cardiology Annual Scientific Session (ACC 2026). MOMENTUM screened 1,086 patients with resistant hypertension (as defined by the American Heart Association’s criteria ) and found that 27.3 percent, or 297 patients had hypercortisolism. This finding complements the results of Corcept’s CATALYST trial, which found hypercortisolism in 23.8 percent of the 1,057 patients screened with difficult-to-control type 2 diabetes. The prevalence of hypercortisolism in patients who had hemoglobin A1c (HbA1c) of 7.5 percent or higher and were taking 3 or more blood pressure medicines was 32.6 percent in MOMENTUM and 36.6 percent in CATALYST. “Resistant hypertension increases the risk of cardiovascular events like heart attacks, strokes, and heart failure, as well as kidney damage,” said Deepak L. Bhatt, M.D., M.P.H., M.B.A., Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai. “MOMENTUM shows that hypercortisolism contributes to resistant hypertension in over a quarter of patients and that screening for hypercortisolism in these challenging-to-treat patients may help physicians provide more personalized care.” Dr. Bhatt presented the data as Featured Clinical Research at ACC 2026, is a lead investigator and steering committee member for MOMENTUM, and a paid consultant to Corcept Therapeutics. “It is now clear that hypercortisolism is more common than previously assumed in patients whose hypertension and diabetes don’t respond to standard-of-care treatments,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “We are grateful to the investigators and patients who have participated in this research and hope that the findings will provide critical information to support increased screening for hypercortisolism, more accurate diagnoses and improved treatment options.” About MOMENTUM MOMENTUM was the largest US-based trial ever conducted to assess the prevalence of hypercortisolism in patients with resistant hypertension. A total of 1,086 patients were screened at 50 sites across the United States. All patients had resistant hypertension as defined by the American Heart Association’s criteria (systolic blood pressure greater or equal to 130 mmHg despite taking 3 or more blood-pressure lowering medications, including a diuretic, or taking 4 or more blood-pressure lowering medications). Using a simple, standardized 1-mg dexamethasone suppression test (DST), 27 percent of these patients were found to have hypercortisolism. About Hypercortisolism Hypercortisolism, also known as Cushing’s syndrome, is caused by excessive activity of the hormone cortisol. Symptoms vary, but most patients experience one or more of the following manifestations: hypertension, central obesity, elevated blood sugar and difficult-to-control type 2 diabetes, severe fatigue and weak muscles. Irritability, anxiety, depression and cognitive disturbances are common. Hypercortisolism can affect every organ system and can be fatal if not treated effectively. Cardiovascular events are the most common cause of death. Recent research shows that endogenous hypercortisolism is more prevalent than previously believed. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders, leading to the discovery of more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with Cushing’s syndrome, solid tumors, ALS and liver disease. In 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with endogenous Cushing’s syndrome, and in 2026, the company introduced Lifyorli™, approved in combination with nab-paclitaxel, the first FDA-approved selective glucocorticoid receptor antagonist for adults with platinum-resistant ovarian cancer. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com . Contacts Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com

Drug ApprovalAHAClinical Study

27 Mar 2026

·www.biospace.com

Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant)

LOUISVILLE, Ky., March 26, 2026 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI™ (relacorilant), which is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. 1 “We are extremely excited to announce our partnership with Corcept Therapeutics as the exclusive national specialty pharmacy for LIFYORLI, which reflects the growing need for accessible, well-supported treatment options in rare and complex oncology care,” said Benito Fernandez, Chief Commercial Officer. “Onco360 is focused on simplifying the path to therapy while delivering high-touch, clinical support for patients and their caregivers.” LIFYORLI is a reversible glucocorticoid receptor (GR) antagonist. In functional in vitro assays with the mineralocorticoid receptor, LIFYORLI showed no agonist or antagonist activity. In human cell line-derived xenograft models, LIFYORLI enhanced apoptosis and antitumor activity when administered with paclitaxel. Cortisol binding to the GR is immunosuppressive, decreasing secretion of pro‑inflammatory cytokines. GR antagonism may indirectly activate the immune system; LIFYORLI inhibited the cortisol-induced reduction of tumor necrosis factor alpha and interferon gamma in stimulated peripheral blood mononuclear cells. LIFYORLI’s approval was based on the pivotal phase 3 ROSELLA study, which enrolled 381 patients with platinum-resistant ovarian cancer who had received one to three prior lines of therapy, at least one of which included bevacizumab. 2 Patients were randomized 1:1 to receive either LIFYORLI plus nab-paclitaxel or nab-paclitaxel monotherapy. The ROSELLA study met its dual primary endpoints of progression-free and overall survival. The most common (>20%) adverse reactions include laboratory abnormalities, decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite. 1 Please read the full prescribing information for LIFYORLI. About Onco360 Oncology Pharmacy Onco360 is the nation’s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com . Media Contact: Benito Fernandez, Chief Commercial Officer Benito.fernandez@onco360.com 516-640-1332 References: LIFYORLI™ (relacorilant) [Package Insert]. Redwood City, CA. Corcept Therapeutics. 2026. 2 Olawaiye, A, Gladieff, L, et al. ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer. JCO 43. (2025). DOI:10.1200/JCO.2025.43.17_suppl.LBA5507

Phase 3Clinical Result

26 Mar 2026

·www.pharmaceutical-technology.com

Corcept’s first-in-class ovarian cancer drug gains FDA approval

Lifyorli is the first selective glucocorticoid receptor agonist to get the FDA’s blessing. Credit: Marko Aliaksandr / Shutterstock.com Corcept Therapeutics has secured US approval for its selective glucocorticoid receptor agonist, Lifyorli (relacorilant), in ovarian cancer more than three months before its Prescription Drug User Fee Act (PDUFA) date of 11 July. This means that the drug will soon be available alongside nab-paclitaxel to American patients with platinum chemotherapy-resistant ovarian, fallopian tube or primary peritoneal cancer. Lifyorli is specifically indicated for patients who have received one-to-three prior treatments, including at least one course of Roche’s VEGF-A blocker, Avastin (bevacizumab). The FDA greenlit Lifyorli based on the results of the Phase III ROSELLA study (NCT05257408), which found that the drug plus nab-paclitaxel significantly boosted both progression-free survival (PFS) and overall survival (OS) over nab-paclitaxel alone in patients with refractory, platinum-resistant disease. Lifyorli’s approval will be welcome news for Corcept, which ran into a regulatory roadblock back in December 2025 when the FDA refused to give the drug the OK in hypertension linked to Cushing’s syndrome. The news looks to have pleased investors too, as Corcept’s stock value climbed more than 18.5% on the Nasdaq exchange from $34.15 at market open on 25 March pre-news debut to $40.47 at close the same day following the approval announcement. Now, with one indication under Lifyorli’s belt, Corcept is hoping to expand the drug’s utility to several other indications, including endometrial, cervical, prostate and pancreatic cancer. Lifyorli is currently the only selective glucocorticoid receptor agonist on the US market. Lifyorli’s market potential Now that Lifyorli is approved for use in the ovarian cancer setting, Rob Coleman, gynaecologic oncologist at Texas Oncology, notes that the drug is poised to become “a new standard of care (SoC) treatment”. Jasminemay Barcelon, senior oncology analyst at GlobalData, echoed this sentiment, noting that Lifyorli’s potential to resensitise tumours to platinum-based chemotherapy could prolong the drug’s duration of benefit and drive its potential as a SoC choice. Barcelon added that its mechanism of action does not require a level of glucocorticoid receptor (GR) tumour expression, so the drug may capture uptake in patients lacking established ovarian cancer biomarkers like folate receptor alpha. Currently, there are few options for patients with refractory, platinum-resistant ovarian cancer, as the SoC revolves around non-platinum-based chemotherapy such as nab-paclitaxel or topotecan. While targeted therapies like Avastin and antibody-drug conjugate (ADC) Elahere (mirvetuximab soravtansine) are available, patients are left with few options when they relapse following treatment with these therapies – leaving a treatment gap, which Corcept hopes Lifyorli will fill. GlobalData, parent company of Pharmaceutical Technology , currently forecasts a blockbuster future for Lifyorli, with the drug expected to generate $2bn in 2031.

Drug ApprovalClinical ResultPhase 3ADC

100 Deals associated with Relacorilant

External Link

KEGG	Wiki	ATC	Drug Bank
D11336	Relacorilant	-	DB14976

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Platinum-Resistant Epithelial Ovarian Carcinoma	United States	Corcept Therapeutics, Inc.	25 Mar 2026
Platinum-Resistant Fallopian Tube Carcinoma	United States	Corcept Therapeutics, Inc.	25 Mar 2026
Platinum-Resistant Primary Peritoneal Carcinoma	United States	Corcept Therapeutics, Inc.	25 Mar 2026

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Platinum-Resistant Ovarian Carcinoma	NDA/BLA	United States	Corcept Therapeutics, Inc.	14 Jul 2025
Cushing Syndrome	NDA/BLA	United States	Corcept Therapeutics, Inc.	30 Dec 2024
Ovarian Cancer	Phase 3	United States	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	United States	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Argentina	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Australia	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Belgium	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Brazil	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Canada	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	France	Corcept Therapeutics, Inc.	29 Jun 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ROSELLA (ESGO2026)	Phase 3	Platinum-Resistant Ovarian Carcinoma	234	Relacorilant + nab-paclitaxel	gsoxsxynus(vigapuibnf) = pwezvfzkjz zstgvzyfbk (zqokkdblsr, 5.38 - 9.53) View more	Positive	28 Feb 2026
				nab-paclitaxel	pyxaidlqjx(rucqqjnzmg) = vbqyutlwzo tkaudixqfe (pzhbzurjek ) View more
NCT05726292 (ASCO_GU2026)	Phase 2	Localized Prostate Carcinoma Neoadjuvant	90	LHRH agonist/antagonist + Enzalutamide + Relacorilant	ktcpbhzfsw(qbgnuownxz): P-Value = 0.15 View more	Positive	26 Feb 2026
				LHRH agonist/antagonist + Enzalutamide + Placebo
NCT04308590 (GRADIENT, CTgov)	Phase 3	Cushing Syndrome \| Adrenocortical Adenoma	137	Placebo+Relacorilant (Relacorilant)	odllmkfkbj(llduvwxcul) = bsvtsramuh agwbhqgpga (uvyebbjfzp, pgbovlwjoj - nccxjoysod) View more	-	03 Aug 2025
				Placebo (Placebo)	odllmkfkbj(llduvwxcul) = ylvbssevrw agwbhqgpga (uvyebbjfzp, udfmrbofga - qixgmdmpyo) View more
NCT05257408 (ROSELLA \| GOG-3073 \| ENGOT-ov72, ESMO_GCC2025)	Phase 3	Platinum-Resistant Ovarian Carcinoma	381	Relacorilant + nab-paclitaxel	keqziweqcp(xotxreahse) = eeasboolux basuavchlj (eociztwktj ) View more	Positive	19 Jun 2025
				nab-paclitaxel	keqziweqcp(xotxreahse) = hdpixhbord basuavchlj (eociztwktj ) View more
NCT03776812 (Study-552, CTgov)	Phase 2	Recurrent Platinum-Resistant Primary Peritoneal Carcinoma \| Recurrent ovarian cancer \| Recurrent Primary Peritoneal Carcinoma ... View more	178	Nab-paclitaxel+Relacorilant (Arm A: Continuous Relacorilant Dosing)	mkbphknsmy(sxjhzeahna) = gyfhrfekuj tphntiscua (mwfajiydpf, gxamqzhesj - wjawiaslan) View more	-	30 Apr 2025
				Nab-paclitaxel+Relacorilant (Arm B: Intermittent Relacorilant Dosing)	mkbphknsmy(sxjhzeahna) = ivtmkfathe tphntiscua (mwfajiydpf, adkibvshjn - ykffeezazg) View more
NCT03697109 (GRACE, CTgov)	Phase 3	Endogenous Cushing Syndrome	152	Relacorilant (Relacorilant (RW Phase))	jjszzlwxqa = xelnvqogzd pqfdruztim (jpmkisyhgt, mfpuoyxxtb - lvjkspeopp) View more	-	24 Apr 2025
				Placebo (Placebo (RW Phase))	jjszzlwxqa = gebuqdyllt pqfdruztim (jpmkisyhgt, mpxacuptci - aaagretmgt) View more
NCT05257408 (ROSELLA, Company_Website \| NEWS) Manual	Phase 3	Platinum-Resistant Ovarian Carcinoma	381	Relacorilant + nab-paclitaxel	wxwmvvbssk(qnrpdcrrzi) = laorihnity qklhnoklxf (hausxnrqrn, 5.55 - 7.43) Met View more	Positive	31 Mar 2025
				Nab-paclitaxel	wxwmvvbssk(qnrpdcrrzi) = fidctpfugn qklhnoklxf (hausxnrqrn, 3.94 - 5.88) Met View more
NCT03604198 (BusinessWire) Manual	Phase 3	Cushing Syndrome	116	Relacorilant	xzjdjvoqbz(glnkqbvkpn) = At month 24 of the study, patients exhibited clinically meaningful and statistically significant reductions in mean systolic blood pressure (10.0 mm Hg; p-value: 0.012) and mean diastolic blood pressure (7.3 mm Hg; p-value: 0.016), compared to their measurement at entry into the long-term extension study. rcpprsifbo (mpzvqghskg ) View more	Positive	16 Dec 2024
NCT03604198 (Company_Website) Manual	Phase 2	Cushing Syndrome	53	Relacorilant	udumoaxzlo(adytwmluoh) = ozedkdokkt sbrajfrvac (sarexlnndm ) View more	Positive	25 Nov 2024
NCT04308590 (GRADIENT, Biospace) Manual	Phase 3	Cushing Syndrome	137	relacorilant	suwykdigfw(dxnbacbzoe) = lrgrjwevbx tvqnwpqgwm (nevdvadpyg ) Met	Positive	30 Oct 2024
				Placebo	suwykdigfw(dxnbacbzoe) = jyykvjuafy tvqnwpqgwm (nevdvadpyg ) Met

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis